(Q36863482)

16 August 2017

1 reference

title

Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer (English)

1 reference

16 August 2017

1 reference

1 reference

Graham A Colditz

2

0 references

author name string

Wendy Y Chen

series ordinal

1

1 reference

PubMed ID

17597706

16 August 2017

language of work or name

1 reference

1 July 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

1 reference

16 August 2017

4

1 reference

16 August 2017

7

1 reference

16 August 2017

415-423

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0851

16 August 2017

0 references

cites work

Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial. The PEPI Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

Relation between estrogen receptor concentration and clinical and histological factors: their relative prognostic importance after radical mastectomy for primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Estrogen receptors and distinct patterns of breast cancer relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

The shape of age-incidence curves of female breast cancer by hormone-receptor status.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Ethnicity and breast cancer: factors influencing differences in incidence and outcome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Concordance among gene-expression-based predictors for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Gene expression profiles of primary breast tumors maintained in distant metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Alcohol consumption and breast cancer: estrogen receptor status and histology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Reproductive risk factors for breast cancer by receptor status, histology, laterality and location

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Risk factors for breast cancer according to estrogen and progesterone receptor status

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Changes in self-reported family history of breast cancer with change in case-control status

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Potential for bias in case-control studies of oral contraceptives and breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

A comparison of prospective and retrospective assessments of diet in the study of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Alcohol and Breast Cancer in Women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Serum hormones and the alcohol-breast cancer association in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Effect of ethanol on proliferation and estrogen receptor-alpha expression in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Alcohol and endogenous sex steroid levels in postmenopausal women: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Alcohol consumption and breast cancer oestrogen and progesterone receptor status.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Hormone replacement therapy in relation to breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Relationship between long durations and different regimens of hormone therapy and risk of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Prognostic characteristics in breast cancers after hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Low biologic aggressiveness in breast cancer in women using hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Adult weight change and risk of postmenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Nurses' health study: log-incidence mathematical model of breast cancer incidence

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

What can be learnt from models of incidence rates?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Breast cancer risk prediction with a log-incidence model: evaluation of accuracy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Unopposed estrogen therapy and the risk of invasive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0851

7 January 2021

Identifiers

DOI

10.1038/NCPONC0851

1 reference

PubMed ID

17597706

Dimensions Publication ID

16 August 2017

0 references

1 reference

PubMed ID

17597706